ARGX (argenx N.V.) שולי רווח גולמי ממכירות

argenx SE relies on the sales of a single immune drug, expanding its application across various diseases. Historical gross margin reflects profitability trends, where the value of 89.50 corresponds to the current metric. Growth potential is driven by unique antibodies and the blockbuster Vyvgart. Business flexibility is maintained by fully outsourcing production and testing to external partners.
פילוחי מדדים מקיפים ואנליטיקה עבור argenx SE (ARGX)

argenx SE dominates the autoimmune disease therapy segment thanks to its high-profit drug Vyvgart. Gross margin measures the share of profit after deducting direct production costs, reflecting the efficiency of cost-of-sales management. For the investor, this ratio serves as an indicator of the company's pricing power and the stability of its cash flows. An analysis of production margins confirms the business's ability to monetize unique medical demand without increasing operating expenses.